BNTC
Benitec Biopharma Inc. · NASDAQ · Healthcare · USD · 10-K for 2026, filed 2026-09-14
Figures on this page computed 2026-11-08 12:40 UTC
Last close
9.54USD
Market data, 2026-11-06
Except where said otherwise: 10-K for 2026, filed 2026-09-14
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2026
- Accession
- 0001193125-26-390570
- Reported in
- USD
- computed
- 10-K for 2026, filed 2026-09-14
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2026
- Accession
- 0001193125-26-390570
- Reported in
- USD
- 10-K for 2026, filed 2026-09-14
- 10-K for 2026, filed 2026-09-14
- 10-K for 2026, filed 2026-09-14
- 10-K for 2026, filed 2026-09-14
- 10-K for 2026, filed 2026-09-14
- 10-K for 2026, filed 2026-09-14
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2026
- Accession
- 0001193125-26-390570
- Reported in
- USD
- 10-K for 2026, filed 2026-09-14
- 10-K for 2026, filed 2026-09-14
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2026
- Accession
- 0001193125-26-390570
- Reported in
- USD
- 10-K for 2026, filed 2026-09-14
- 10-K for 2026, filed 2026-09-14
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2026
- Accession
- 0001193125-26-390570
- Reported in
- USD
- 10-K for 2026, filed 2026-09-14
- 10-K for 2026, filed 2026-09-14
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Growth is the furthest below its sector's middle: 0.35 against 0.46 on the market's range.
- Growth-20.1%35 of 100, below its sector
- Returns on capital-25.7%24 of 100, above its sector
- Marginsn/anot placed
- Price2.5x37 of 100, below its sector
- Safety34.0099 of 100, above its sector
- What it pays outn/anot placed
- Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Five bars, one line
lens 7 of 9Each against its own average
3 of 5 readExcept where said otherwise: 10-K for 2026, filed 2026-09-14
- Salesn/a
Its own average over 8 years, 1.7M.
- Profit2.63x
Its own average over 10 years, -17.3M.
- Free cash flow1.28x
Its own average over 10 years, -13.0M.
- Debtn/a
Its own average over 0 years.
- Price0.05x
Its own average over 11 years, 190. Market data, 2026-11-06
Profit is furthest from its own average, at 2.63 times.
Profit is 2.63 times its own 10-year average; Free cash flow is 1.28 times its own 10-year average; Price is 0.05 times its own 11-year average.
Every figure in this lens
Except where said otherwise: 10-K for 2026, filed 2026-09-14
Sales against its own 8-year averagen/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2026
- Accession
- 0001193125-26-390570
- Reported in
- USD
Profit against its own 10-year average2.63
- Source
- filed
- Statement
- income
- Fiscal year
- 2026
- Accession
- 0001193125-26-390570
- Reported in
- USD
Free cash flow against its own 10-year average1.28
- Source
- filed
- Statement
- income
- Fiscal year
- 2026
- Accession
- 0001193125-26-390570
- Reported in
- USD
Debt against its own 0-year averagen/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2026
- Accession
- 0001193125-26-390570
- Reported in
- USD
Price against its own 11-year average0.05Market data, 2026-11-06
- Source
- market
- Taken on
- 2026-11-06
- Reported in
- USD